The function of insulin receptor substrate-1 (IRS-1) is regulated by both tyrosine and serine/threonine phosphorylation. Phosphorylation of some serine/threonine residues in IRS-1 dampens insulin signaling, whereas phosphorylation of other serine/threonine residues enhances insulin signaling. Phosphorylation of human IRS-1 at Ser 629 was increased by insulin in Chinese hamster ovary cells expressing the insulin receptor (1.26 ؎ 0.09-fold; P < 0.05) and L6 cells (1. M ANY PROTEINS ARE regulated by tyrosine phosphorylation, and others are regulated by phosphorylation on serine and threonine residues. Insulin receptor substrate-1 (IRS-1), a central component of both insulin and IGF-I signaling, is tyrosine phosphorylated by the insulin or IGF-I receptor in response to hormone activation of the receptor. The phosphotyrosine residues that reside in pYXXM motifs serve as recognition sites for proteins that contain Src homology 2 (SH2) domains, such as the p85 regulatory subunit of phosphatidylinositol (PI) 3Ј-kinase (1). Besides being tyrosine phosphorylated, IRS-1 also is phosphorylated heavily on serine and threonine residues. Serine and threonine residues account for 242 of the 1242 total amino acids in the IRS-1 sequence, about 20% total. A number of specific serine and threonine phosphorylation sites have been identified (2-16), and some have the ability either to decrease (2, 12) or enhance (10) insulin signaling. Some sites may function either as positive or negative modulators of insulin signaling, depending upon the particular experimental conditions (17).
The function of insulin receptor substrate-1 (IRS-1) is regulated by both tyrosine and serine/threonine phosphorylation. Phosphorylation of some serine/threonine residues in IRS-1 dampens insulin signaling, whereas phosphorylation of other serine/threonine residues enhances insulin signaling. Phosphorylation of human IRS-1 at M ANY PROTEINS ARE regulated by tyrosine phosphorylation, and others are regulated by phosphorylation on serine and threonine residues. Insulin receptor substrate-1 (IRS-1), a central component of both insulin and IGF-I signaling, is tyrosine phosphorylated by the insulin or IGF-I receptor in response to hormone activation of the receptor. The phosphotyrosine residues that reside in pYXXM motifs serve as recognition sites for proteins that contain Src homology 2 (SH2) domains, such as the p85 regulatory subunit of phosphatidylinositol (PI) 3Ј-kinase (1) . Besides being tyrosine phosphorylated, IRS-1 also is phosphorylated heavily on serine and threonine residues. Serine and threonine residues account for 242 of the 1242 total amino acids in the IRS-1 sequence, about 20% total. A number of specific serine and threonine phosphorylation sites have been identified (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , and some have the ability either to decrease (2, 12) or enhance (10) insulin signaling. Some sites may function either as positive or negative modulators of insulin signaling, depending upon the particular experimental conditions (17) .
Ser 312 (Ser 307 in the rat and mouse IRS-1 sequence) has been the focus of considerable research as a negative regulator of IRS-1 function (2, 4, 9, 18) . This site originally was identified as a potential c-jun N-terminal kinase phosphorylation site that decreases association of IRS-1 with the insulin receptor (IR) (2) , likely due to the proximity of Ser 312 to the phosphotyrosine binding domain of IRS-1 (amino acid residues 160 -263). More recently, Ser 312 has been implicated in inflammation and lipid-induced insulin resistance (19) . On the other hand, Ser 1223 , which was identified using in vitro kinase assays and mass spectrometry analysis, appears to have a positive role in IRS-1 function. A mutation of Ser 1223 to alanine increases association of the tyrosine phosphatase SH2-containing phosphatase-2 (SHP-2) with IRS-1 and decreases insulin-stimulated IRS-1 tyrosine phosphorylation (10) . Proximity of phosphorylated Ser 1223 to the SH2 recognition motifs responsible for association of SHP-2 with IRS-1 may interfere with this binding event.
Using mass spectrometry analysis of recombinant human IRS-1 (hIRS-1) proteins phosphorylated in vitro with various serine kinases, we recently reported a number of novel phosphorylation sites in this protein (16 
Materials and Methods

Experimental subjects
A lean, healthy subject with normal glucose tolerance (75 g oral glucose tolerance test) underwent a percutaneous biopsy of the vastus lateralis muscle under local anesthesia, under basal conditions, as previously described (21) . The protocol was approved by the Arizona State University Institutional Review Board, and informed written consent was obtained from the volunteer.
Cell lines, cDNAs, and antibodies
The Chinese hamster ovary (CHO) cell line overexpressing the human IR was a gift from Dr. Feng Liu (Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX). The L6 myoblast cell line was a gift from Dr. Amira Klip (Programme in Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada). The cDNA encoding full-length wild-type hIRS-1 was a gift from Dr. C. Ronald Kahn (Department of Medicine, Joslin Diabetes Center, Boston, MA). The cDNA encoding wild-type, CA, and KD Akt were gifts from Dr. Feng Liu.
Anti-HA.11 was purchased from Covance (Berkeley, CA). Anti-Akt, anti-phospho-Akt (Ser 473 ) anti-phospho-IRS-1 (Ser 636/639 ), anti phospho-IRS-1 (Ser 612 ) (Ser 616 in human sequence), and anti-phospho-Akt substrate antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-phospho-IRS-1 (Tyr 632 ) and anti-myc antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), whereas anti-IRS-1 and anti-p85 antibodies were purchased from Upstate (Charlottesville, VA). Akt Inhibitor III was purchased from CAL-BIOCHEM (EMD Biosciences, Inc, San Diego, CA). Active recombinant Akt-1 and ERK-2 were purchased from Upstate.
Construction of plasmids, site-directed mutagenesis, and adenoviruses
The cDNA encoding full-length wild-type hIRS-1 (pBEX-hIRS-1) was described previously (10) . Ser 629 and Ser 636 in hIRS-1 were mutated to Ala (pBEX-hIRS-1-S629A and pBEX-hIRS-1-S636A) with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. For pBEX-hIRS-1-S629A, the sense primer was 5Ј-CCCAGTGGCCGAAAGGGCGCTGGAGAC-TATATGCCC-3Ј, and antisense primer was 5Ј-GGGCATATAGTCTC-CAGCGCCCTTTCGGCCACTGGG-3Ј. For pBEX-hIRS-1-S636A, the sense primer was 5Ј-GACTATATGCCCATGGCCCCCAAGAGCG-TATCTG-3Ј, and antisense primer was 5Ј-CAGATACGCTCTTGGG-GGCCATGGGCATATAGTC-3Ј. The plasmid and mutant sites were verified by restriction digestion and sequencing. Adenoviruses encoding green fluorescence protein (as an adenovirus control) and hIRS-1 (Ad-hIRS-1) were produced as previously described (10) . The cDNA encoding the hIRS-1 539 -706 fragment was generated by PCR using hIRS-1 cDNA (courtesy of Dr. C. Ronald Kahn) as a template. Sac I and Xba I directed sequences were introduced to allow the in-frame insertion of the cDNA into the His-tagged and myc-tagged prokaryotic expression plasmid pTrcHis2 (Invitrogen, Carlsbad, CA). All recombinant plasmid constructs were verified by restriction mapping and DNA sequencing.
Cell culture, transfection. Immunoprecipitation, and Western blot analysis CHO/IR cells were grown in Ham's F-12 medium (Life Technologies, Inc., Invitrogen) and L6 cells in ␣MEM (Life Technologies, Inc., Invitrogen), supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin. Transfections of cells were performed in 60-mm plates with 5 g of each recombinant plasmid, using Lipofectamine (Invitrogen) according to the manufacturer's protocol. In some experiments, cells were transduced with an adenovirus encoding full-length, HAtagged, wild-type hIRS-1 (10). Twenty-four hours after transfection/ after transduction, cells were serum starved for 2-4 h and then treated with or without inhibitors before being exposed to 100 nm insulin for the assigned time. Cells were then washed three times with ice-cold PBS and lysed in 300 -400 l lysis buffer [50 mm HEPES (pH 7.6), 150 mm Na CI, 1% Triton X-100, 10 mm NaF, 20 mm sodium pyrophosphate, 20 mm ␤-glycerol phosphate, 1 mm sodium orthovanadate, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 m microcystin-LR, and 1 mm phenylmethylsulfonyl fluoride]. Cell lysates were centrifuged (10,000 ϫ g, 4 C, 10 min), and the clarified supernatants were used for immunoprecipitation or Western blot experiments. Immunoprecipitation and Western blot analyses were performed as described previously (10) .
Expression of glutathione S-transferase (GST) and His-myc tagged IRS-1 fusion proteins
GST-hIRS-1 524 -698 fusion proteins were expressed as described previously (16) . In brief, XL1-blue cells containing plasmids encoding for recombinant GST-hIRS-1 524 -698 fusion protein or DH5␣ cells containing plasmids encoding for hIRS-1 539 -706 fusion proteins were grown in Luria Broth (LB) medium at 37 C overnight. This culture was diluted 1:10 and grown at 30 C for 3 h. Expression of the fusion proteins was induced by the addition of isopropyl ␤-d-thiogalactoside to a final concentration of 0.2 mm. After 4-h induction, the cells were harvested by centrifugation at 5000 ϫ g for 10 min, washed with 10 mm Tris-HCl (pH 8.0), suspended in bacterial lysis buffer containing 50 mm Tris-HCl (pH 7.5), 50 mm KCl, 1 mm dithiothreitol, 5 mm EDTA, 1 mm phenylmethane sulfonyl fluoride, 0.1% (vol/vol) Triton X-100, and 1 mg/ml lysozyme, and lysed by sonication. Cell lysates were clarified by centrifugation at 12,000 ϫ g for 15 min. GST-IRS-1 524 -698 fusion proteins were purified by affinity chromatography with glutathione-sepharose beads. The His-myc-hIRS-1 539 -706 fusion proteins were purified using Ni-NTA Agarose beads (Invitrogen) following the protocol provided by Invitrogen except that the elution step was omitted so that the His-myc-tagged hIRS-1 would stay bound to the beads.
In vitro kinase assay
hIRS-1 539 -706 fragment proteins adsorbed on the Ni-NTA agarose beads were phosphorylated by in vitro treatment with kinases, including Akt or ERK2, at 30 C for 30 min, using a final volume of 40 l kinase buffer [20 mm HEPES (pH 7.5), 100 mm NaCl, 10 mm MgCl 2 , and 15 m cold ATP]. After extensive washing with PBS, proteins were eluted by boiling at 95 C for 4 min before being subjected to SDS-PAGE. GST-IRS-1 524 -698 fusion proteins were phosphorylated by in vitro treatment with the Akt-1 (Upstate) at 30 C for 30 min, using assay dilution buffer, magnesium/ATP cocktail (Upstate), and [␥-32 P]ATP (PerkinElmer, Boston, MA). The reactions were terminated by addition of SDS-PAGE sample loading buffer and heated at 95 C for 4 min. The proteins were separated on 10% SDS-PAGE gels, stained with Coomassie blue, and phosphorylation was visualized by autoradiography. For mass spectrometry analysis, the in vitro kinase assay was performed with unlabeled ATP instead of [␥-
32 P]ATP.
FIG. 1.
A, CID spectrum of the tryptic peptide hIRS-1 627-638 containing phospho-Ser 629 from L6 myoblasts. HA-tagged hIRS-1 was expressed ectopically in L6 myoblasts. Cells were lysed, IRS-1 was immunoprecipitated using anti-IRS-1 antibody, and immunoprecipitated proteins were resolved by SDS-PAGE. IRS-1 was analyzed by spectrometry as described in the text. B, Comparison of IRS-1 sequence across species. C, CID spectrum of the tryptic peptide hIRS-1 627-638 containing phospho-Ser 629 from human skeletal muscle. A percutaneous biopsy of the vastus lateralis muscle from a healthy volunteer was homogenized, IRS-1 was immunoprecipitated using anti-IRS-1 antibody, and immunoprecipitated proteins were resolved by SDS-PAGE. IRS-1 was analyzed by spectrometry as described in the text.
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Muscle biopsy processing and analysis
Approximately 100 mg (wet weight) human vastus lateralis muscle was homogenized in detergent lysis buffer containing protease and phosphatase inhibitors (21) . IRS-1 was immunoprecipitated from homogenate containing 1 mg Lowry protein, the immunoprecipitated proteins were then resolved on 10% SDS-PAGE gels, and the gels were stained with Coomassie blue. The region of the gel containing IRS-1 was excised; no protein band was visible for IRS-1, but the position of IRS-1 was established in preliminary experiments using immunoblot analysis and confirmed by mass spectrometry. Mass spectrometry analysis was performed as described under Mass spectrometry analysis.
Mass spectrometry analysis
Mass spectrometry analysis was performed as described previously (10, 16) . Briefly, IRS-1 was immunoprecipitated from either human skeletal muscle homogenates, CHO/IR cell lysates, or L6 cell lysates, and the proteins were resolved by 1-D SDS-PAGE. The IRS-1 bands were excised, digested in situ with trypsin, and the resulting peptides were analyzed by HPLC-electrospray ionization tandem mass spectrometry (HPLC-ESI/MS/MS). HPLC-ESI/MS/MS was performed on a Thermo Finnigan LTQ-FT/ICR (San Jose, CA), which has been adapted for nanospray ionization. On-line HPLC separation of the IRS-1 digests was accomplished with a Michrom BioResources MAGIC 2002 micro HPLC (Michrom BioResources, Inc., Auburn, CA), using a PicoFrit column (75 m inner diameter; New Objective, Inc., Woburn, MA) packed to 10 cm with C18 adsorbent (218MS 5 m, 300 Å; Vydac, Hesperia, CA); mobile phase, linear gradient of 2-65% acetonitrile in 0.5% acetic acid/0.005% trifluoroacetic acid followed by a hold at 65% acetonitrile and then a step to 80% acetonitrile; flow rate, 0.4 l/min. Programs used for data analysis include SEQUEST (Thermo Finnigan), Mascot (Matarix Science, London, UK), ProteinProspector (University of California, San Francisco MS facility web site), and GPMAW (Lighthouse Data, Odense, Denmark).
Results
Ser 629 is phosphorylated in cells and regulated by insulin
Lysates of CHO/IR and L6 myoblasts ectopically expressing HA-tagged hIRS-1 were immunoprecipitated with either 32 P]-ATP, separated by SDS-PAGE, stained with Coomassie blue, and phosphorylation was visualized by autoradiography. In a parallel experiment, IRS-1 was phosphorylated in vitro in the presence of unlabeled ATP. The phosphorylated IRS-1 was resolved by SDS-PAGE, the bands containing GST-hIRS-1 524 -698 were excised, and digested by trypsin in situ. The phosphopeptides were analyzed by HPLC-ESI-MS/MS. B, Akt inhibitor decreases phosphorylation of Akt substrate sites in hIRS-1 in cultured cells. CHO/IR cells were transfected with wild-type pBEX-hIRS-1for 24 h. Cells were fasted for 2 h and incubated with Akt inhibitor for 2 h before being exposed to 100 nM insulin for 15 min. Cell lysates were immunoprecipitated with anti-HA and immunoblotted with anti-phospho-Akt substrate antibody. C, Akt inhibitor decreases phosphorylation of hIRS-1 at Ser 629 in cultured cells. CHO/IR cells were transfected with wild-type pBEX-hIRS-1 for 24 h. Cells were fasted for 2 h and incubated with Akt inhibitor for 2 h before being exposed to 100 nM insulin for 15 min. Cell lysates were immunoprecipitated with anti-HA, and the immunoprecipitates were separated by SDS-PAGE. The bands containing hIRS-1 were excised and digested by trypsin in situ. The phosphopeptide (R)KGpSGDYMPMSPK was analyzed by HPLC-ESI-MS/MS. Quantification of Ser 629 phosphorylation was performed as described in the text. The results are the mean Ϯ SE of five independent experiments (*, P Ͻ 0.05 vs. insulin alone). D, CA Akt increases basal Ser 629 phosphorylation in cells. CHO/IR cells were transfected with wild-type, CA, or KD Akt for 24 h, followed by infection with Ad-hIRS-1 for another 24 h. Cells were serum starved for 5 h and then lysed. Cell lysates were immunoprecipitated with anti-HA antibody. Immunoprecipitates of IRS-1 were resolved by SDS-PAGE and subjected to mass spectrometry quantification for Ser 629 phosphorylation (*, P Ͻ 0.05 vs. wild-type; **, P Ͻ 0.05 vs. CA). Results are from three independent experiments. IB, Immunoblot; Ins, insulin; IP, immunoprecipitation; WT, wild-type.
anti-HA or anti-IRS-1 antibodies. Immunoprecipitated proteins were resolved by SDS-PAGE, and the area of the gel corresponding to IRS-1 was analyzed by mass spectrometry. Using a hypothesis driven approach (16, 22) , a peptide monophosphorylated at Ser 629 was identified in both cell types; a typical collision-induced dissociation (CID) spectrum from hIRS-1 expressed in L6 cells is shown in Fig. 1A . Ser 629 is present in human, primate, and pig IRS-1, but the corresponding residue in rat, mouse, and chicken IRS-1 is the hydrophilic amino acid asparagine (Fig. 1B) . To determine whether Akt can phosphorylate Ser 629 in response to insulin in cells, CHO/IR cells were transfected with wild-type pBEX-hIRS-1 for 24 h. The transfected cells were fasted for 2 h and incubated with or without 15 m Akt inhibitor III for 2 h before being exposed to 100 nm insulin for 15 min. IRS-1 was immunoprecipitated from cell lysates, and the immunoprecipitated IRS-1 was immunoblotted with an anti-phospho-Akt substrate antibody, which detects phosphorylated amino acid sequence motifs for Akt. Figure  2B shows that phosphorylation of Akt substrate sites in hIRS-1 is stimulated by insulin, and this insulin stimulation decreases upon incubation of the cells with Akt inhibitor. Although this experiment shows the effectiveness of the Akt inhibitor in reducing insulin-stimulated phosphorylation of these sites, it is not specific. To determine whether the Akt inhibitor specifically inhibited insulin stimulation of Ser 629 phosphorylation, immunoprecipitated IRS-1 from the same experiments used to obtain the results in Fig. 2B was resolved by SDS-PAGE, the band containing IRS-1 was excised from the gel, and the proteins digested in situ with trypsin. The resulting peptides were analyzed and quantified by HPLC-ESI/MS/MS. Figure 2C shows that insulin-stimulated phosphorylation of Ser 629 specifically was inhibited by preincubation with Akt inhibitor III, suggesting that Akt is a Ser Immunoprecipitates of IRS-1 were resolved by SDS-PAGE and subjected to mass spectrometry quantification for Ser 629 phosphorylation. Figure 2D shows ), might influence the phosphorylation or function of these two sites. To address this, site-directed mutagenesis was used to generate HA-tagged S629A and S636A mutant IRS-1 proteins. HAtagged pBEX-hIRS-1, pBEX-hIRS-1 S629A, and pBEX-hIRS-1 S636A were transfected into CHO/IR cells for 24 h. Cells were serum starved for 4 h before being exposed to 100 nm insulin for 15 min. The immunoprecipitated proteins were analyzed for phosphorylation at Ser . As expected, the S636A mutant showed little or no immunoreactivity with the anti-phospho-Ser 636/639 antibody (Fig. 3, A and B) . When Ser 629 was mutated to alanine to prevent phosphorylation at this site, both basal and insulinstimulated phosphorylation at Ser 636 were increased. Quantification of these results is shown in Fig. 3B . In contrast, phosphorylation at neither Tyr 632 nor Ser 616 was affected by the S629A mutation (Fig. 3, C and D, respectively) , indicating the specificity of this phenomenon.
To gain more insight into the effect of Ser 629 phosphorylation on Ser 636 phosphorylation, time course experiments were performed in the presence of insulin using wild-type and S629A mutant IRS-1 proteins expressed in CHO/IR cells. Cells were serum starved for 2 h before being exposed to 100 nm insulin for 0, 1, 5, 15, 30, 60, and 120 min. Cell lysates were immunoprecipitated using anti-HA antibody, and immunoprecipitates were subjected to immunoblots for Ser 636 phosphorylation. The results are shown in Fig. 4A . Phosphorylation of Ser 636 in wildtype IRS-1 increased by 15 min reached a maximum at 30 min and returned toward basal values thereafter. In IRS-1 in which phosphorylation at Ser 629 was prevented by the S629A mutation, Ser 636 phosphorylation increased more rapidly, peaking by 15 min, before returning to baseline. Quantification of the results of three such independent experiments is shown in Fig.  4B , demonstrating the leftward shift in Ser 636 phosphorylation caused by the S629A mutation.
Ser 629 phosphorylation improves downstream insulin signaling
In light of data suggesting Ser 636 phosphorylation negatively regulates insulin signaling (12), we hypothesized that because the S629A mutant possesses increased Ser 636 phosphorylation, the S629A mutation in IRS-1 would decrease downstream insulin signaling. This hypothesis, if confirmed, would provide evidence that phosphorylation of Ser 629 positively modulates downstream insulin signaling. To test this, we assessed association of the p85 regulatory subunit of PI 3Ј-kinase with wild-type and S629A mutant IRS-1. CHO/IR cells were transfected with wild-type pBEX-hIRS-1 or mutant pBEX-hIRS-1S629A. Twenty-four hours after transfection, cells were serum starved for 4 h before being exposed to 100 nm insulin for 15 min. Cells were lysed, and cell lysates were immunoprecipitated with an anti-p85 antibody. The immunoprecipitates were analyzed for coprecipitated hIRS-1 by immunoblotting. Figure 5A shows the results of a typical experiment, and Fig. 5B is the quantification data for five independent experiments. The results demonstrate that prevention of Ser 629 phosphorylation decreases insulin-stimulated association of p85 with IRS-1, under the same conditions that increase Ser 636 phosphorylation. To analyze further downstream insulin signaling, we tested the ability of insulin to increase Akt phosphorylation at Ser 473 in CHO/IR cells ectopically expressing either wild-type or S629A mutant IRS-1. As can be seen in Fig. 6, A and B , as was the case for inhibited p85 association with IRS-1, cells expressing the S629A mutant showed significantly decreased Akt phosphorylation, again supporting the notion that phosphorylation at Ser 629 positively regulates insulin signaling.
Phosphorylation of IRS-1 in vitro with Akt inhibits phosphorylation of Ser 636/639 by ERK
Together, the aforementioned data suggest that by phosphorylating Ser 629 , Akt can enhance downstream insulin signaling by enhancing association of the p85 regulatory subunit of PI 3Ј-kinase with IRS-1, and this effect may be mediated by regulating the level of Ser 636 phosphorylation. To test whether phosphorylation of IRS-1 in this region by Akt directly interferes with the subsequent phosphorylation of Ser 636 , a His-tagged fragment of IRS-1 containing Ser 629 and Ser 636 (hIRS-1 539 -706 ) was expressed in E. coli and purified using nickel beads. hIRS-1 539 -706 , still coupled to the beads, was subjected to an in vitro kinase assay with Akt or no added kinase as a control. After washing to remove Akt, a second kinase reaction was performed using ERK as the kinase. The hIRS-1 539 -706 was resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with an antibody directed against phospho-Ser 636/639 . The results of three independent experiments showed that phosphorylation of this region of IRS-1 with Akt, under conditions known to phosphorylate Ser 629 (see Fig. 2A ), reduced subsequent phosphorylation of Ser 636/639 by ERK (Fig. 7, A and B) . This finding supports the hypothesis that Ser 629 phosphorylation is involved in regulating the level of Ser 636 phosphorylation.
Discussion
Although it has long been known that tyrosine phosphorylation of IRS-1 is required for the downstream transmission of the insulin signal, serine and threonine phosphorylation of IRS-1 is emerging as an important regulatory feature of insulin action. A large number of phosphorylation sites have been identified in IRS-1, and many of these sites are reported to affect the function of this protein (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Some sites appear likely to be negative regulators of IRS-1 signaling. For example, Ser 312 (Ser 307 in the rodent IRS-1 sequence) is phosphorylated in response to inflammatory stimuli that activate kinases such as c-jun N-terminal kinase (JNK)and inhibitor B kinase (IKK) (2, 9, 14, 19, 23) . Ser 312 lies in close proximity to the phosphotyrosine binding domain of IRS-1, and evidence from yeast trihybrid experiments indicates that phosphorylation at this site interferes with the interaction between IRS-1 and the IR (2). Furthermore, some evidence supports the notion that excessive phosphorylation at Ser 312 is important for lipid-induced insulin resistance (19) . Other sites appear to be positive regulators of IRS-1 function. In this regard, Ser 1223 , which we identified in a mass spectrometry screening, is involved in regulation of SHP-2-mediated dephosphorylation of tyrosine residues of IRS-1 (10) . Ser 1223 lies in proximity to an SH2 recognition motif used by SHP-2 to associate with IRS-1 (24) . When Ser 1223 is phosphorylated, interaction between SHP-2 and IRS-1 is decreased, and IRS-1 tyrosine phosphorylation increases (10) .
Ser 636 is a well-recognized phosphorylation site in IRS-1, and the preponderance of evidence suggests that Ser 636 phosphorylation can negatively influence insulin signaling (12, 20 (25) , which is known to inhibit downstream insulin signaling (12, 20) .
The results of this study show that Akt phosphorylates Ser 629 in vitro, that most, if not all, of the insulin-stimulated increase in Ser 629 phosphorylation can be attributed to Akt in cells, and that phosphorylation of this region of IRS-1 by Akt interferes with phosphorylation of Ser 636 . Together, these data suggest the model for interactions in this region of IRS-1 shown in Fig. 8 . According to this model, after insulin-induced phosphorylation of Tyr 632 and subsequent activation of PI 3Ј-kinase, Akt is phosphorylated and activated rapidly. Active Akt then phosphorylates IRS-1 at Ser 629 . This delays the activation of a negative feedback loop involving IRS-1 phosphorylation at Ser 636 by some unknown mechanism, perhaps steric hindrance, thus lessening the dampening effect of Ser 636 phosphorylation on Tyr 632 function. Therefore, phosphorylation of IRS-1 at Ser 629 enhances and sustains insulin signaling.
The results of these studies lead us to propose that insulininduced phosphorylation at Ser 629 represents a feed-forward mechanism to enhance insulin action in humans. By extension, factors interfering with phosphorylation at Ser 629 could be candidates for factors that cause insulin resistance. 
